Development of 10-Hydroxycamptothecin-crizotinib conjugate based on the synergistic effect on lung cancer cells

References

• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021;71:209–49.
   PubMed Web of Science ®Google Scholar
• Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv192–237.
   PubMed Web of Science ®Google Scholar
• Melosky B, Cheema P, Juergens RA, et al. The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer. Ther Adv Med Oncol. 2021;13:17588359211056306.
   Web of Science ®Google Scholar
• Tan AC, Tan DSW. Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol. 2022;40:611–25.
   PubMed Web of Science ®Google Scholar
• Tan CS, Kumarakulasinghe NB, Huang YQ, et al. Third generation EGFR TKIs: current data and future directions. Mol Cancer. 2018;17:29.
   PubMed Web of Science ®Google Scholar
• Zhu L, Ye D, Lei T, et al. Cancer mutation profiles predict ICIs efficacy in patients with non-small cell lung cancer. Expert Rev Mol Med. 2022;24:e16.
   PubMed Web of Science ®Google Scholar
• Hayashi H, Nadal E, Gray JE, et al. Overall treatment strategy for patients with metastatic NSCLC with activating EGFR mutations. Clin Lung Cancer. 2022;23:e69–82.
   PubMed Web of Science ®Google Scholar
• Liu C, Yu H, Long Q, et al. Real world experience of crizotinib in 104 patients with ALK rearrangement non-small-cell lung cancer in a single Chinese Cancer Center. Front Oncol. 2019;9:1116.
   PubMed Web of Science ®Google Scholar
• Liu Z, Li H, Fan Y, et al. Combination treatment with Rhizoma paridis and Rhizoma curcuma longa extracts and 10-hydroxycamptothecin enhances the antitumor effect in H22 tumor model by increasing the plasma concentration. Biomed Pharmacother. 2016;83:627–34.
   PubMed Web of Science ®Google Scholar
• Liu Z, Zheng Q, Chen W, et al. Chemosensitizing effect of Paris saponin I on camptothecin and 10-hydroxycamptothecin in lung cancer cells via p38 MAPK, ERK, and Akt signaling pathways. Eur J Med Chem. 2017;125:760–9.
   PubMed Web of Science ®Google Scholar
• Liu Z, Fu Q, Wang Y, et al. Synergy between vinorelbine and afatinib in the inhibition of non-small cell lung cancer progression by EGFR and p53 signaling pathways. Biomed Pharmacother. 2021;134:111144.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Hong T, Tong L, et al. Astragalus polysaccharide combined with 10-hydroxycamptothecin inhibits metastasis in non-small cell lung carcinoma cell lines via the MAP4K3/mTOR signaling pathway. Int J Mol Med. 2018;42:3093–104.
   PubMed Web of Science ®Google Scholar
• Meng G, Wang W, Chai K, et al. Combination treatment with triptolide and hydroxycamptothecin synergistically enhances apoptosis in A549 lung adenocarcinoma cells through PP2A-regulated ERK, p38 MAPKs and Akt signaling pathways. Int J Oncol. 2015;46:1007–17.
   PubMed Web of Science ®Google Scholar
• Heigener DF, Reck M. Crizotinib. Recent Results Cancer Res. 2018;211:57–65.
   PubMedGoogle Scholar
• Wang W, Wang H, Lu P, et al. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study. J Transl Med. 2019;17:52.
   PubMed Web of Science ®Google Scholar
• Ma Z, Wang Y, Sun Y, et al. Efficacy of crizotinib combined with chemotherapy in treating advanced non-small-cell lung cancer and effect on patients’ quality of life and adverse reaction rate. J Healthc Eng. 2022;2022:7898737.
   PubMed Web of Science ®Google Scholar
• Elefantova K, Lakatos B, Kubickova J, et al. Detection of the mitochondrial membrane potential by the cationic dye JC-1 in L1210 cells with massive overexpression of the plasma membrane ABCB1 drug transporter. IJMS. 2018;19:1985.
   Google Scholar
• Roboz GJ, Rosenblat T, Arellano M, et al. International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia. J Clin Oncol. 2014;32:1919–26.
   PubMed Web of Science ®Google Scholar
• Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 2009;28 Suppl 1:S24–S31.
   PubMedGoogle Scholar
• Graham RP, Treece AL, Lindeman NI, et al. Worldwide frequency of commonly detected EGFR mutations. Arch Pathol Lab Med. 2018;142:163–7.
   PubMed Web of Science ®Google Scholar
• Yang Z, Yang N, Ou Q, et al. Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients. Clin Cancer Res. 2018;24:3097–107.
   PubMed Web of Science ®Google Scholar
• Noronha V, Patil VM, Joshi A, et al. Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer. JCO. 2020;38:124–36.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Asahina H, Kishimoto J, et al. Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: an open-label, randomised phase 2 clinical trial. Eur J Cancer. 2021;149:14–22.
   PubMed Web of Science ®Google Scholar
• Gu ZB, Liao LM, Yao GJ, et al. Patient with EGFR-mutant lung cancer harboring de novo MET amplification successfully treated with gefitinib combined with crizotinib. Curr Probl Cancer. 2021;45:100702.
   PubMed Web of Science ®Google Scholar
• Liu Z, Jiang L, Li Y, et al. Cyclosporine A sensitizes lung cancer cells to crizotinib through inhibition of the Ca2(+)/calcineurin/Erk pathway. EBioMedicine. 2019;42:326–39.
   PubMed Web of Science ®Google Scholar
• Ayoub NM, Alkhalifa AE, Ibrahim DR, Alhusban A. Combined crizotinib and endocrine drugs inhibit proliferation, migration, and colony formation of breast cancer cells via downregulation of MET and estrogen receptor. Med Oncol. 2021;38:8.
   PubMed Web of Science ®Google Scholar
• Chen K, Lv F, Xu G, et al. Phosphoproteomics reveals ALK promote cell progress via RAS/JNK pathway in neuroblastoma. Oncotarget. 2016;7:75968–80.
   PubMedGoogle Scholar
• Ogura H, Nagatake-Kobayashi Y, Adachi J, et al. TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity. Sci Rep. 2017;7:5519.
   PubMed Web of Science ®Google Scholar
• Hafeez U, Parakh S, Gan HK, Scott AM. Antibody-Drug Conjugates for Cancer Therapy. Molecules. 2020;25:4764.
   PubMed Web of Science ®Google Scholar
• Chen F, Zhao Y, Pan Y, et al. Synergistically enhanced therapeutic effect of a carrier-free HCPT/DOX nanodrug on breast cancer cells through improved cellular drug accumulation. Mol Pharm. 2015;12:2237–44.
   PubMed Web of Science ®Google Scholar
• Zhuang C, Guan X, Ma H, et al. Small molecule-drug conjugates: a novel strategy for cancer-targeted treatment. Eur J Med Chem. 2019;163:883–95.
   PubMed Web of Science ®Google Scholar
• А Zolottsev V, Latysheva АS, Pokrovsky VS, et al. Promising applications of steroid сonjugates for cancer research and treatment. Eur J Med Chem. 2021;210:113089.
   PubMed Web of Science ®Google Scholar
• Hosseini-Zare MS, Sarhadi M, Zarei M, et al. Synergistic effects of curcumin and its analogs with other bioactive compounds: a comprehensive review. Eur J Med Chem. 2021;210:113072.
   PubMed Web of Science ®Google Scholar